^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MLL-AF4 fusion

    i
    Entrez ID:
    27125
    Related biomarkers:
    Fusion
    10ms
    Application and prognostic relevance of CD34 detection in immunophenotyping of pediatric acute B lymphoblastic leukemia. (PubMed, Eur Rev Med Pharmacol Sci)
    A higher positive rate of bone marrow CD34 expression in children with B-ALL is associated with a favorable prognosis. Children with negative CD34 expression are relatively more prone to MRD and tumor relapse after chemotherapy.
    Retrospective data • Journal • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD38 (CD38 Molecule) • CD22 (CD22 Molecule) • CD33 (CD33 Molecule) • CD34 (CD34 molecule) • PBX1 (PBX Homeobox 1) • CD79A (CD79a Molecule) • MME (Membrane Metalloendopeptidase) • ANPEP (Alanyl Aminopeptidase, Membrane)
    |
    CD34 positive • MLL-AF4 fusion
    11ms
    Chromatin and aberrant enhancer activity in KMT2A rearranged acute lymphoblastic leukemia. (PubMed, Curr Opin Genet Dev)
    Recent work has shown that the MLL-AF4 fusion protein drives aberrant enhancer activity at key oncogenes in ALL, dependent on the continued presence of MLL-AF4 complex components. As well as providing some general insights into enhancer function, these observations may also provide an explanation for transcriptional heterogeneity observed in MLLr patients.
    Review • Journal
    |
    KMT2A (Lysine Methyltransferase 2A)
    |
    MLL rearrangement • MLL-AF4 fusion